

**REVIEW Article**

# Migrainous Infarction and Cortical Spreading Depression

Waleed Iftikhar<sup>1</sup>, Fatima Fayyaz Cheema<sup>1,\*</sup>, Sneha Khanal<sup>2</sup>, Qudsia Umaira Khan<sup>1,\*</sup>

<sup>1</sup> CMH Lahore Medical College and Institute of Dentistry (NUMS), Lahore, Pakistan

<sup>2</sup> Jahurul Islam Medical College and Hospital, Bajitpur, Kishoregonj, Bangladesh

\*Corresponding authors: *Fatima Fayyaz Cheema and Qudsia Umaira Khan*, CMH Lahore Medical College and Institute of Dentistry, Abdur Rehman Road, Lahore Cantt, Pakistan; fatimafayyazcheema94@icloud.com and drqudsia@yahoo.com respectively.

*Submitted: June 30, 2020; Revised: July 13, 2020; Accepted: July 16, 2020; Published: August 12, 2020*

*Citation: Iftikhar W, Cheema FF, Khana S, Khan QU. Migrainous Infarction and Cortical Spreading Depression. Discoveries 2020, 8(3): e112. DOI: 10.15190/d.2020.9*

## ABSTRACT

Migraine is a very common disorder of the nervous system. It shares similar physiological processes with stroke. Migrainous infarction is a rare complication of migraine with aura. The neurological symptoms of migraine aura correspond to the cortical spreading depression and this depression can lead to a migrainous infarction. It is pertinent to state that the investigation and detection of the cortical depression might have a great clinical significance. Blood vessels in the cranium play an important role in the pathophysiology of migraine. In the case of injured states of brain, the cortical spreading depression causes extreme vasoconstriction rather than vasodilation. The endothelial damage caused by the cortical spreading depression can result in hypercoagulability, leading to an increased risk of stroke. There are many genetic disorders in which migraine and stroke are the major symptoms and an insight into these disorders can help us in the understanding of complex mechanisms of migrainous infarction. It is pertinent to state that some derangements in the vascular function accompany migraine which may also serve as targets for research and treatment. This article will describe the hemodynamic and genetic relationship between migraine induced stroke and how it relates to the cortical spreading depression.

## Keywords

Migrainous infarction, cortical spreading depression, migraine, migraine with aura.

## Abbreviations

World Health Organization (WHO); electroencephalogram (EEG); direct current (DC); International Classification of Headache Disorders (ICHD); magnetic resonance imaging (MRI); computed tomography scan (CT Scan); positron emission tomography (PET); von Willebrand factor (VWF); endothelial micro particles (EMPs); retinal vasculopathy with cerebral leukodystrophy (RVCL); cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); methylenetetrahydrofolate reductase (MTHFR); insulin receptor (INSR); estrogen receptor 1 (ESR1); cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL); notch receptor 3 (NOTCH3); HtrA serine peptidase 1 (HTRA1); three prime repair exonuclease 1 (TREX1); collagen type IV alpha 1 chain (COL4A1); mitochondrially encoded tRNA leucine 1 (MT-TL1); hereditary infantile hemiparesis, retinal arteriolar tortuosity and leukoencephalopathy (HIHRATL); mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS); familial hemiplegic migraine 1 (FHM1); familial hemiplegic migraine 2 (FHM2); familial hemiplegic migraine 3 (FHM 3); calcium voltage-gated channel subunit alpha 1 A (CACNA1A); ATPase Na<sup>+</sup>/K<sup>+</sup> transporting subunit alpha 2 (ATP1A2); sodium voltage-gated channel alpha subunit 1 (SCN1A); potassium channel subfamily K member 18 (KCNK18); episodic ataxia type 2 (EA2); casein kinase 1 isoform delta (CSNK1D); spinocerebellar ataxia type 6 (SCA6); familial advanced sleep-phase syndrome 2 (FASPS2); alpha-protein kinase 1 (ALPK1); retinopathy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome; proline-rich transmembrane protein 2 (PRRT2); paroxysmal nonkinesigenic dyskinesia (PNKD); solute carrier family 1 member 3 (SLC1A3); collagen type IV alpha 2 chain (COL4A2); solute carrier family 2 member 1 (SLC2A1); solute carrier family 4 member 4 (SLC4A4); tissue plasminogen (tPA).

## **SUMMARY**

1. *Introduction*
2. *Pathology and etiology of cortical spreading depression*
3. *Signs and symptoms of migrainous infarction*
4. *Diagnosis of migrainous infarction*
5. *The link between migrainous infarction and cortical spreading depression*
  - 5.1. *Hemodynamic implications*
  - 5.2. *Coagulation disorders*
  - 5.3. *Genetic implications*
6. *Treatment*
7. *Directions for future research*
8. *Conclusion*

### **1. Introduction**

Migraine is a complex neurovascular disorder. It affects about one fifth of the population, among which 20-30% people experience sensory, motor and visual symptoms along with headache, a condition called as the migraine aura<sup>1</sup>. Migraine can progress through four stages, which are prodrome, aura, attack and post-drome, respectively. However, it is not necessary that everyone who has migraine goes through all these stages. Prodrome is the beginning of a migraine attack occurring few days or few hours before the migraine. The symptoms experienced during this phase include: mood changes, cravings for specific foods, fatigue, yawning, and sensitivity to light or sound. The prodromal phase can be followed by the aura phase in which the patient usually suffers from visual disturbances and numbness or tingling on one side of the body, symptoms that can last for 5-60 minutes. The third phase, the “attack”, also known as the “headache phase”, is characterized by stabbing pain either affecting one or both sides of the head along with sensitivity to light, nausea and anxiety and the symptoms lasting for 4-72 hours. The trigemino-vascular pathway is considered to be responsible for the debilitating headache observed in this phase. Post-drome, also called the “migraine hangover”, the last phase of migraine, is characterized by fatigue, lack of concentration, and neck stiffness, occurring in almost 80% of the patients and lasting for about 24-48 hours<sup>2-4</sup>.

Migraines are most probably due to brain ischemia, vascular pathologies or neurophysiological events e.g. cortical spreading depression. The same migraine-causing mechanisms may induce an

infarction, potentially through a vasospasm. A migrainous infarction is a rare type of an ischemic stroke which occurs in correspondence with migraine aura symptoms. In migrainous strokes, the migraine must occur with aura. Migrainous strokes are rare and account for only 0.8 percent of all strokes. Typically, women under the age of 45 who experience migraine with aura are at the greatest risk for developing migrainous infarction, especially when combined with smoking and use of oral contraceptives. The symptoms of migraine aura can mimic the symptoms of a stroke, which is a leading cause of death across the world. According to the World Health Organization (WHO) about 15 million people have stroke worldwide each year. Evidences abound as to the relationship between migraine and vascular disorders, subclinical lesions of the brain and cortical depression. There are various mechanisms that may play a role in the link between cerebrovascular disorders and migraine<sup>5-7</sup>.

This review covers the pathology and etiology of cortical spreading depression, signs and symptoms and diagnosis of migrainous infarction. It highlights the link between migrainous infarction and cortical spreading depression through hemodynamic implications, coagulation disorders and genetic implications. It also briefly describes the treatment for migraine induced stroke and the directions for future research.

### **2. Pathology and etiology of cortical spreading depression**

Studies show that the mechanisms causing the migraine can lead to an infarction. Cortical spreading depression is a neurophysiological event causing migraine which can also induce an infarction, potentially through a vasospasm.

In cortical spreading depression, there is the depression of spontaneous and evoked electroencephalogram (EEG) activity. This depression spreads across the cortical surface at the rate of 2 mm to 5 mm. The marked depression of spontaneous EEG lasts for about 30 seconds to a minute, returning to the normal in 5 to 10 minutes. Conversely, the evoked synaptic activity takes at least 15 to 30 minutes to recover<sup>8, 9</sup>. Propagating field oscillations precedes the neuronal and glial depolarization, which is spreading, covering up to 1 mm in distance<sup>10</sup>. A small state of hyper-excitability is indicated by these oscillations, which may relate

to the observation of cortical spreading depression and seizures, in the same patients with acutely injured cerebral cortex<sup>11</sup>. A total loss of neuronal activity follows the oscillations, which may last for minutes, before complete recovery. At the same time, director current (DC) potential becomes negative with an amplitude within the range of 15 to 30 mV for 60 seconds<sup>12</sup>. Completely sustained depolarization may attempt to explain the negative shift in DC potential which is restricted to the unique cell domains, because at first, there is a rapid opening of conductance along a greater part of the pyramidal neuron accompanied by a centripetal closure in the direction of the apical dendrites<sup>13</sup>. There may also be some contribution from local increases in tissue resistivity<sup>14</sup>. Hence, it is possible that neurons may play a role in the current signals that initiate cortical spreading depolarization, and also for those that play a role in its propagation and determination<sup>15</sup>.

The depression of the activity seen with the EEG is caused by an acute failure of homeostasis of brain ions, and efflux of amino acids from the neurons, which is in some way similar to the ischemic penumbra<sup>16, 17</sup>. During cortical spreading depression, there is an increase in the concentration of potassium ions in the extracellular fluid, up to 60 mmol/L from 30 mmol/L. Conversely, calcium ions concentration decreases from 0.1 mmol/L to 0.2 mmol/L, while chloride concentration decreases from 120 mmol/L to 70 mmol/L<sup>18, 19</sup>. At the same time, there is a decline in pH from 7.3 to ~ 6.9, while there is also a 50% decrease in extracellular space dimensions to help regulate the movement of water into the neurons<sup>20</sup>. Movement of water into the dendrites results in reversible swelling of the neurons and alteration of dendritic spines while astrocyte volume remains constant<sup>21, 22, 23</sup>. This is in line with the involvement of neurons in cortical spreading depression. There is the spontaneous normalization of concentration of ions and extracellular space dimensions after 30 seconds to a minute, but the concentration of calcium ions and the extracellular pH (pH<sub>e</sub>) takes more time to recover.

A large concentration of amino acids, including aspartate and glutamate are released during the wave of depolarization<sup>24, 25</sup>. Voltammetric recordings have indicated that the large release of transmitter accompanies the onset of depolarization<sup>26</sup>. This implies that the release of neurotransmitters may

only play a secondary role in the spread of cortical spreading depression. Currently, we are yet to understand the mechanism by which cortical spreading depression is initiated. However, slight elevation in the level of potassium ions and transmitters are enough to start the spread of cortical spreading depression<sup>27</sup>.

Cortical spreading depression is explained through the following flowchart (Figure 1)<sup>28, 29</sup>.

### **3. Signs and symptoms of migrainous infarction**


A person having a stroke or infarction during the course of migraine with aura is said to have migrainous infarction. The symptoms which are observed in patients of migraine with aura are most commonly visual symptoms such as flashes of light. However, sensory, language, and motor symptoms are also observed. These symptoms include dysarthria (which may or may not be present), hyperactivity, hypoactivity, depression, cravings for specific food items, frequent yawning, fatigue, neck stiffness and pain, numbness or tingling on one side of the body or face, lack of concentration, sensitivity to light, sound, nausea and pallor. The symptoms of migraine with aura have been listed in the Table 1 below<sup>30</sup>.

Whenever blood supply to the brain is compromised, the brain cells and tissues start dying due to lack of supply of oxygen and nutrients. The symptoms of an ischemic stroke are dizziness, weakness or numbness especially on side of the body, severe headache, aphasia, visual disturbance, dysarthria, impaired consciousness, nystagmus and ataxia. The symptoms of an ischemic stroke have been listed in the Table 2 below<sup>31, 32</sup>.

Most of the symptoms of migraine with aura and an ischemic stroke are overlapping. The major symptom of a migrainous infarction is visual aura (82.3%), closely accompanied by aphasia and sensory dysfunction. Symptoms that are also present include aphasia, mild hemiparesis, tetraparesis, and deficit in the visual field<sup>31</sup>.

### **4. Diagnosis of migrainous infarction**

The International Classification of Headache Disorders (ICHD) is the basis for diagnosis<sup>33</sup>. Based on the ICHD criteria, at least 60-minute aura attack and premonitory migraine with aura diagnosis is necessary for the diagnosis of migrainous infarction.



**Figure 1: Mechanism of cortical spreading depression<sup>28, 29</sup>**

An observation of an ischemic infarction using different neuroimaging techniques, such as Magnetic

Resonance Imaging (MRI) and Computed Tomography Scan (CT Scan) in the migraine

**Table 1: Symptoms of migraine with aura<sup>30</sup>**

Symptoms of migraine with aura
<ul style="list-style-type: none"><li>• Hyperactivity</li><li>• Hypoactivity</li><li>• Depression</li><li>• Cravings for specific food items</li><li>• Frequent yawning</li><li>• Fatigue</li><li>• Neck stiffness</li><li>• Neck pain</li><li>• Aphasia</li><li>• Dysarthria may or may not be present</li><li>• Visual disturbance</li><li>• Flashes of light</li><li>• Numbness or tingling on one side of face/body/tongue</li><li>• Difficulty in concentration</li><li>• Sensitivity to light</li><li>• Sensitivity to sound</li><li>• Nausea</li><li>• Pallor</li></ul>

**Table 2: Symptoms of an ischemic stroke<sup>31, 32</sup>**

Symptoms of an ischemic stroke
<ul style="list-style-type: none"><li>• Dizziness</li><li>• Weakness, especially on one side of the body</li><li>• Numbness, especially on one side of the body</li><li>• Severe headache</li><li>• Visual disturbance</li><li>• Aphasia</li><li>• Dysarthria</li><li>• Impaired consciousness</li><li>• Nystagmus</li><li>• Ataxia</li></ul>

associated area adds confirmation to the diagnosis. Migrainous infarction occurs more frequently in the posterior circulation (70.6%-82.0%) as compared to the anterior circulation.

It is very difficult to differentiate between migraine with aura and a stroke, because symptoms of migraine with aura can mimic the symptoms of a stroke. However, one distinct feature that

distinguishes the two is that the symptoms of migraine with aura develop gradually over a time of at least five minutes, while in the case of a stroke the symptoms are very sudden. A person with migraine with aura could have experienced the same symptoms multiple times. However, in the case of a stroke the symptoms are new for the person.

In many cases, the prognosis is usually favorable, exhibiting complete recovery or just a few residual symptoms, which may be very minor<sup>34,35</sup>.

## **5. The link between migrainous infarction and cortical spreading depression**

Ischemic strokes occur when blood vessels to the brain are blocked, restricting blood flow. Cortical spreading depression, which is considered to be the underlying cause of migraine with aura, can lead to extreme vasoconstriction in case of injured states of brain. Thus, blood supply to the brain is compromised, leading to an infarction. Secondly, few studies suggest that cortical spreading depression damages the endothelium, which can result in hypercoagulability. This can also contribute to the chances of an infarction. There are many genetic disorders related to migraine and stroke. Better insights can help us in better understanding the migraine and its complex diversities.

### *5.1. Hemodynamic implications*

It has been widely accepted that cortical spreading depression serves as a major pathogenic mechanism of migrainous infarction. The aura phase is the starting point of cerebral oligemia, it spreads interiorly in a gradual fashion, accompanied by hyperemia in an attack of migraine aura<sup>36,37</sup>. Patients without migraine aura also exhibit posterior hypoperfusion in an attack, as indicated by Positron Emission Tomography (PET) and MR perfusion studies<sup>38,39</sup>. When there is an inversion of the hemodynamic response to cortical spreading depression, mostly in pathological conditions, then the spreading depression may trigger extreme vasoconstriction rather than vasodilation<sup>40</sup>. However, the incidence of migrainous infarction is quite rare notwithstanding the high prevalence of the disorder, hence cerebral blood flow even at the oligemic phase of cortical spreading depression stands above the ischemic threshold. Alongside the oligemia itself, animal models of cortical spreading depression have shown ipsilateral release of matrix

metalloprotease induced by depolarization, and subsequently, compromised integrity of the blood brain barrier<sup>41</sup>. There is also increased matrix metalloprotease in human migraineurs, especially during headache-free periods and in migraine attacks. When combined, cortical spreading depression, which is a special pathophysiologic mechanism of migrainous infarction, may trigger an ischemic stroke.

Vascular response to cortical spreading depression in a healthy brain and in a damaged brain is described in the Figure 2 and Figure 3<sup>42</sup>.


### *5.2. Coagulation disorders*

Studies have shown increased levels of Von Willebrand factor (VWF), platelet-activating factor and platelet aggregation during migraine episodes<sup>43-45</sup>. Platelet-activating factor is released from platelets, mast cells, and cerebral endothelial cells in response to calcitonin gene-related peptide and hypoxia. This in turn triggers the release of VWF. It is the VWF that activates the IIIa and IIb platelet receptors. Coagulation abnormalities include an increased level of prothrombin fragment 1.2, the deficiency of Protein S, and a reduced resistance to activated protein C<sup>46,47</sup>.


According to a study higher levels of endothelial micro particles (EMPs), platelets, red blood cells (RBCs), VWF antigen, fibrinogen, tissue plasminogen and activator antigen are reported in female patients with migraine with aura while monocytic and platelet micro particles are increased in all patients with migraine with aura. Stromal cell-derived factor-1 alpha, which is responsible for maintaining the integrity of the endothelium is deficient in women with migraine with aura. All these factors are responsible for causing hypercoagulability, increasing the risk of stroke in patients with migraine with aura. However, we are yet to understand whether plasma hypercoagulability results from or is the cause of cortical spreading depression. One theory says that cortical spreading depression can cause endothelial damage. Thus, we can infer that hypercoagulability caused by this endothelial damage can lead to an infarction<sup>48</sup>.

### *5.3. Genetic implications*

Cortical spreading depression presents the waves of depolarized glial cells and neurons propagating in a slow pattern accompanied by a sustained suppression of spontaneous activities in the neurons.



**Figure 2: Vascular response to cortical spreading depression in the normal state of the brain<sup>42</sup>**



**Figure 3: Vascular response to cortical spreading depression in the injured states of the brain<sup>42</sup>**

Imaging studies of patients suffering migraine have shown acute changes in brain activity and blood

flow with features similar to those of cortical spreading depression, involved in visual aura

**Table 3: Migraine and stroke related disorders and their associated genes and clinical presentations<sup>50-52</sup>**

Disease	Gene Mutation	Clinical Presentation
<b>Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)</b>	Notch Receptor 3 ( <i>NOTCH3</i> )	Migraine with aura Encephalopathy Seizures Motor weakness
<b>Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL)</b>	HtrA Serine Peptidase 1 ( <i>HTRA1</i> )	Lacunar infarcts Presence of non-neurological symptoms such as spondylosis and baldness
<b>Retinal vasculopathy with cerebral leukodystrophy (RVCL)</b>	Three Prime Repair Exonuclease 1 ( <i>TREX1</i> )	Migraine Visual disturbance Mini strokes Cognitive impairment
<b>Hereditary infantile hemiparesis, retinal arteriolar tortuosity and leukoencephalopathy (HIHRATL)</b>	Collagen Type IV Alpha 1 Chain ( <i>COL4A1</i> )	Variable features, including both neurological and systemic symptoms Occurring in young children and adults
<b>Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS)</b>	Mitochondrially encoded tRNA leucine 1 ( <i>MT-TL1</i> )	Found in children Migraine with abdominal disturbances Seizures Hearing loss
<b>Familial hemiplegic migraine 1 (FHM1)</b>	Calcium Voltage-Gated Channel Subunit Alpha1 A ( <i>CACNA1A</i> )	Migraine with aura Hemiparesis Seizures Memory loss Coma
<b>Familial hemiplegic migraine 2 (FHM2)</b>	ATPase Na <sup>+</sup> /K <sup>+</sup> Transporting Subunit Alpha 2 ( <i>ATP1A2</i> )	Migraine with aura Hemiparesis Seizures Memory loss Coma
<b>Familial hemiplegic migraine 3 (FHM3)</b>	Sodium Voltage-Gated Channel Alpha Subunit 1 ( <i>SCN1A</i> )	Migraine with aura Hemiparesis Seizures Memory loss Coma

migraine. Although the meninges are innervated by trigeminal nerves and plays a role in the genesis of migraine headaches, the mechanisms by which

migraine is triggered remains controversial and not well understood. Studies on animal models have shown that the trigeminovascular afferents are

**Table 3: Continued**

Disease	Gene Mutation	Clinical Presentation
<b>Mendelian Migraine with Aura</b>	Potassium channel subfamily K member 18 ( <i>KCNK18</i> )	Typical migraine with aura
<b>Episodic Ataxia type 2 (EA2)</b>	Calcium Voltage-Gated Channel Subunit Alpha1 A ( <i>CACNA1A</i> )	Migraine Nystagmus Loss of balance and coordination Vertigo Muscle weakness
<b>Spinocerebellar Ataxia type 6 (SCA6)</b>	Calcium Voltage-Gated Channel Subunit Alpha1 A ( <i>CACNA1A</i> )	Migraine Nystagmus Cerebellar atrophy Tingling and burning Disarthria
<b>Familial Advanced Sleep-Phase Syndrome 2 (FASPS2)</b>	Casein Kinase 1 Isoform Delta ( <i>CSNK1D</i> )	Migraine with aura Abnormal circadian rhythms
<b>Retinopathy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) Syndrome</b>	Alpha-protein kinase 1 ( <i>ALPK1</i> )	Migraine Splenomegaly Ocular dysfunction Heatstroke Inability to perspire
<b>Paroxysmal Dyskinesia Disorders</b>	Proline-rich transmembrane protein 2 ( <i>PRRT2</i> ) Paroxysmal Nonkinesigenic Dyskinesia ( <i>PNKD</i> ) Solute Carrier Family 1 Member 3 ( <i>SLC1A3</i> )	Hemiplegic migraine Attacks of involuntary movements
<b>Collagen Type IV Alpha 1/2 Chain (COL4A1/A2) disorders</b>	Collagen Type IV Alpha 1 Chain ( <i>COL4A1</i> ) Collagen Type IV Alpha 2 Chain ( <i>COL4A2</i> )	Stroke Eye defects Migraine Cardiac arrhythmia Hemolytic anemia

activated by cortical spreading depression and evokes a series of events in the brainstem and cortical meninges that are consistent with the development of headaches<sup>49</sup>.

Three familial hemiplegic migraines have been identified. These encode ion transporters, implying

that alterations in neurotransmitter and ion balances in the brain play a role in this migraine type. Other monogenic syndromes, such as retinal vasculopathy with cerebral leukodystrophy (RVCL), cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) may

give some molecular insight into the pathophysiology of migraine. There have been convincing replications of many genetic associations with potential migraine genes, such as methylenetetrahydrofolate reductase (*MTHFR*), insulin receptor (*INSR*) and estrogen receptor 1 (*ESR1*). Different syndromes and diseases which have association with migraine, stroke and migraine-induced stroke are described in the Table 3<sup>50, 51, 52</sup>.

There are several genes reported to be rarely mutated in case of the hemiplegic migraine (HM). These are *PRRT2*, *PNKD*, *SLC2A1*, *SLZ1A3*, and *SLC4A4*. These genes have been listed in the Table 4<sup>51, 53</sup>.

Studies on the genome-wide associations may be a successful strategy toward the identification of genes that enhance the susceptibility to migraine.

## 6. Treatment

The treatment of migraine-induced infarction is the same as for a typical infarction, including aspirin, which is a blood thinner to prevent clot formation, aspirin plus dipyridamole, warfarin for patients with atrial fibrillation, carotid endarterectomy, clopidogrel, and tissue plasminogen (tPA), which can breakdown clots. The treatment options of migraine-induced stroke have been listed in the Table 5<sup>54</sup>.

## 7. Directions for future research

Identification of the unique signaling pathways that regulate the brain's susceptibility to the development of cortical spread depression may create opportunities for therapeutic modulation of those pathways.

**Table 4: Rarely mutant genes reported in HM<sup>51, 53</sup>**

Rarely mutant genes reported in HM
<ul style="list-style-type: none"><li>• Proline-rich transmembrane protein 2 (<i>PRRT2</i>)</li><li>• Paroxysmal Nonkinesigenic Dyskinesia (<i>PNKD</i>)</li><li>• Solute Carrier Family 2 Member 1 (<i>SLC2A1</i>)</li><li>• Solute Carrier Family 1 Member 3 (<i>SLC1A3</i>)</li><li>• Solute Carrier Family 4 member 4 (<i>SLC4A4</i>)</li></ul>

**Table 5: Treatment options for migraine induced infarction<sup>54</sup>**

Treatment options of migraine induced infarction
<ul style="list-style-type: none"><li>• Aspirin</li><li>• Aspirin plus dipyridamole</li><li>• Warfarin for patients with atrial fibrillation</li><li>• Carotid endarterectomy</li><li>• Clopidogrel</li><li>• Tissue plasminogen (tPA)</li></ul>

Studies have shown that antiepileptic drugs may cause prevention of migraine and cortical spreading disorder<sup>55, 56, 57</sup>. However, in patients whose cerebral cortex has been acutely injured, these medications may have unpredictable effects resulting in the development of cortical spreading depression and even seizures in the presence of antiepileptic drugs (even in high doses), that in normal circumstances can decrease neuronal excitability<sup>58</sup>. There is a need for further studies to investigate whether a change in the antiepileptic medication used (typically phenytoin) may prove effective in reducing the susceptibility to cortical spreading depression initiation<sup>58</sup>.

## 8. Conclusion

Migrainous infarction is a very rare pathogenic event encountered in clinical practice. The exact mechanisms responsible for the migraine-induced stroke remains unclear. However, cortical spreading depression corresponds to the neurological symptoms observed in the disease. The people who are migraineurs should be advised to control other risk factors for stroke, such as diabetes, obesity and hypertension, etc. The patients with recurrent attacks of migraine with aura should be suspected of cerebral ischemia, and neuroimaging should be performed for early diagnosis and prevention of complications.

## Conflict of interest

The authors declare no conflicts of interest.

## Acknowledgments

We express gratitude to our principal, Major General Professor Doctor Abdul Khaliq Naveed (R), and to our host institution, CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan, for supporting our research endeavors.

## References

1. Timm FP, Houle TT, Grabitz SD, et al. Migraine and risk of perioperative ischemic stroke and hospital readmission: hospital based registry study. *BMJ*. 2017;356:i6635.
2. Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. *Headache*. 2018;58 Suppl 1:4-16.
3. Cuvellier JC. Pediatric vs. Adult Prodrome and Postdrome: A Window on Migraine Pathophysiology? *Front Neurol*. 2019;10:199. Published 2019 Mar 8.

4. Charles A. The pathophysiology of migraine: implications for clinical management. *Lancet Neurol*. 2018;17(2):174-182.
5. Rodrigo R, Fernández-Gajardo R, Gutiérrez R, et al. Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities. *CNS Neurol Disord Drug Targets*. 2013;12(5):698-714.
6. Otlivanchik O, Liberman AL. Migraine as a Stroke Mimic and as a Stroke Chameleon. *Curr Pain Headache Rep*. 2019;23(9):63.
7. Gryglas A, Smigiel R. Migraine and Stroke: What's the Link? What to Do? *Curr Neurol Neurosci Rep*. 2017;17(3):22.
8. Leao AAP. Spreading depression of activity in cerebral cortex. *J Neurophysiol*. 1944; 7:359–390.
9. Grafstein B. Mechanism of spreading cortical depression. *J Neurophysiol*. 1956; 19:154–171.
10. Larrosa B, Pastor J, Lopez-Aguado L, Herreras O. A role for glutamate and glia in the fast network oscillations preceding spreading depression. *Neuroscience*. 2006; 141:1057–1068.
11. Fabricius M, Fuhr S, Willumsen L, Dreier JP, Bhatia R, Boutelle MG, Hartings JA, Bullock R, Strong AJ, Lauritzen M. Association of seizures with cortical spreading depression and peri-infarct depolarisations in the acutely injured human brain. *Clin Neurophysiol*. 2008; 119:1973–1984.
12. Leao AA. The slow voltage variation of cortical spreading depression of activity. *Electroencephalogr Clin Neurophysiol*. 1951; 3:315–321.
13. Canals S, Makarova I, Lopez-Aguado L, Largo C, Ibarz JM, Herreras O. Longitudinal depolarization gradients along the somatodendritic axis of CA1 pyramidal cells: a novel feature of spreading depression. *J Neurophysiol*. 2005; 94:943–951.
14. Makarova J, Gomez-Galan M, Herreras O. Variations in tissue resistivity and in the extension of activated neuron domains shape the voltage signal during spreading depression in the CA1 in vivo. *Eur J Neurosci*. 2008; 27:444–456.
15. Kunkler PE, Hulse RE, Schmitt MW, Nicholson C, Kraig RP. Optical current source density analysis in hippocampal organotypic culture shows that spreading depression occurs with uniquely reversing currents. *J Neurosci*. 2005; 25:3952–3961.
16. Vyskocil F, Kritz N, Bures J. Potassium-selective microelectrodes used for measuring the extracellular brain potassium during spreading depression and anoxic depolarization in rats. *Brain Res*. 1972; 39:255–259.

17. Strong AJ, Venables GS, Gibson G. The cortical ischaemic penumbra associated with occlusion of the middle cerebral artery in the cat: 1. Topography of changes in blood flow, potassium ion activity, and EEG. *J Cereb Blood Flow Metab.* 1983; 3:86–96.
18. Kraig RP, Nicholson C. Extracellular ionic variations during spreading depression. *Neuroscience.* 1978; 3:1045–1059.
19. Mutch WAC, Hansen AJ. Extracellular Ph changes during spreading depression and cerebral-ischemia—mechanisms of brain Ph regulation. *J Cereb Blood Flow Metab.* 1984; 4:17–27.
20. Pusic AD, Mitchell HM, Kunkler PE, Klauer N, Kraig RP. Spreading depression transiently disrupts myelin via interferon-gamma signaling. *Experimental Neurology* 2015; 264:43-54.
21. Rasmussen R, O'Donnell J, Ding F, Nedergaard M. Interstitial ions: A key regulator of state-dependent neural activity? *Prog Neurobiol.* 2020;193:101802.
22. Kow LM, Harreveld A. Ion and water movements in isolated chicken retinas during spreading depression. *Neurobiology.* 1972; 2:61–69.
23. Takano T, Tian GF, Peng WG, Lou NH, Lovatt D, Hansen AJ, Kasischke KA, Nedergaard M. Cortical spreading depression causes and coincides with tissue hypoxia. *Nat Neurosci.* 2007; 10:754–762.
24. Zhou N, Gordon GRJ, Feighan D, MacVicar BA. Transient swelling, acidification, and mitochondrial depolarization occurs in neurons but not astrocytes during spreading depression. *Cereb Cortex.* 2010; 20:2614–2624.
25. Van Harreveld A, Fifkova E. Glutamate release from the retina during spreading depression. *J Neurobiol.* 1970; 2:13–29.
26. Fabricius M, Jensen LH, Lauritzen M. Microdialysis of interstitial amino acids during spreading depression and anoxic depolarization in rat neocortex. *Brain Res.* 1993; 612:61–69.
27. Rogers ML, Leong CL, Gowers SA et al. Simultaneous monitoring of potassium, glucose and lactate during spreading depolarization in the injured human brain - Proof of principle of a novel real-time neurochemical analysis system, continuous online microdialysis. *J Cereb Blood Flow Metab.* 2017;37(5):1883-1895.
28. Somjen GG. Aristides Leão's discovery of cortical spreading depression. *J Neurophysiol.* 2005;94(1):2-4. doi:10.1152/classicessays.00031.2005
29. Ayata C, Lauritzen M. Spreading Depression, Spreading Depolarizations, and the Cerebral Vasculature. *Physiol Rev.* 2015;95(3):953-993.
30. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia.* 2013;33(9):629-808.
31. Pancioli, AM, Broderick J, Kothari R, Brott T, Tuchfarber A, Miller R, Khoury J, Jauch E. Public Perception of Stroke Warning Signs and Knowledge of Potential Risk Factors. *JAMA.* 1998; 279 (16): 1288–1292.
32. Khaja A, Grotta, J. Established treatments for acute ischemic stroke. *Lancet.* 2007; 369: 319-30.
33. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia.* 2018; 38(1):1–211.
34. Wolf ME, Szabo K, Griebe M, Forster A, Gass A, Hennerici MG, et al. Clinical and MRI characteristics of acute migrainous infarction. *Neurology.* 2011; 76:1911–1917.
35. Laurell K, Artto V, Bendtsen L, Hagen K, Kallela M, Meyer EL et al. Migrainous infarction: a Nordic multicenter study. *Eur J Neurol.* 2011; 18:1220–1226.
36. Moghaddam B, Schenk JO, Stewart WB, Hansen AJ. Temporal relationship between neurotransmitter release and ion flux during spreading depression and anoxia. *Can J Physiol Pharmacol.* 1987; 65:1105–1110
37. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. *Ann Neurol.* 1981; 9:344–352.
38. Lauritzen M, Skyhoj Olsen T, Lassen NA, Paulson OB. Changes in regional cerebral blood flow during the course of classic migraine attacks. *Ann Neurol.* 1983; 13:633–641.
39. Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. *N Engl J Med.* 1994; 331:1689–1692
40. Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G. Posterior cerebral hypoperfusion in migraine without aura. *Cephalalgia.* 2008; 28:856–862.
41. Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. *Nat Med.* 2011; 17:439–447.

42. Kramer DR, Fujii T, Ohiorhenuan I, Liu CY. Interplay between Cortical Spreading Depolarization and Seizures. *Stereotact Funct Neurosurg.* 2017;95(1):1-5.
43. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, et al. Cortical spreading depression activates and upregulates MMP-9. *J Clin Invest.* 2004; 113:1447–1455.
44. Sarchielli P, Alberti A, Coppola F, Baldi A, Gallai B, Floridi A, et al. Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks. *Cephalalgia.* 2004; 24:623–630.
45. Kovacs K, Herman F, Filep J, Jelencsik I, Magyar K, Csanda E. Platelet aggregation of migraineurs during and between attacks. *Cephalalgia.* 1990; 10:161–165.
46. Cesar JM, Garcia-Avello A, Vecino AM, Sastre JL, Alvarez-Cermeno JC. Increased levels of plasma von Willebrand factor in migraine crisis. *Acta Neurol Scand.* 1995; 91:412–413
47. Moschiano F, D’Amico D, Ciusani E, Erba N, Rigamonti A, Schieronni F, et al. Coagulation abnormalities in migraine and ischaemic cerebrovascular disease: a link between migraine and ischaemic stroke? *Neurol Sci.* 2004; 25 Suppl 3:S126–128
48. Zhang Y, Parikh A, Qian S. Migraine and stroke. *Stroke Vasc Neurol.* 2017 May 29;2(3):160-167.
49. Zhao J, Levy D. Cortical Spreading Depression Promotes Persistent Mechanical Sensitization of Intracranial Meningeal Afferents: Implications for the Intracranial Mechanosensitivity of Migraine. *eNeuro.* 2016;3(6):ENEURO.0287-16.
50. Sutherland HG, Griffiths LR. Genetics of Migraine: Insights into the Molecular Basis of Migraine Disorders. *Headache.* 2017;57(4):537-569.
51. Sutherland HG, Albury CL, Griffiths LR. Advances in genetics of migraine. *J Headache Pain.* 2019;20(1):72. Published 2019 Jun 21.
52. Persico AM, Verdecchia M, Pinzone V, Guidetti V. Migraine genetics: current findings and future lines of research. *Neurogenetics.* 2015;16(2):77-95.
53. Gardiner AR, Jaffer F, Dale RC et al. The clinical and genetic heterogeneity of paroxysmal dyskinesias. *Brain.* 2015;138(Pt 12):3567-3580.
54. Rothwell P, Algra, A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. *Lancet.* 2011; 377:1681-92.
55. Hering-Hanit R, Friedman Z, Schlesinger I, Ellis M. Evidence for activation of the coagulation system in migraine with aura. *Cephalalgia.* 2001; 21:137–139.
56. Marrannes R, Willems R, De Prins E, Wauquier A. Evidence for a role of the N-methyl-D-aspartate (NMDA) receptor in cortical spreading depression in the rat. *Brain Res.* 1988; 457:226–240
57. Martins-Ferreira H, Nedergaard M, Nicholson C. Perspectives on spreading depression. *Brain Res Rev.* 2000; 32:215–234.
58. Ayata C. Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. *Cephalalgia.* 2009; 29:1095–1114.

*This article is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes; 2020, Applied Systems;*